MedTrace Logo

Influence of Alcohol Marketing Stimuli in Adults With Regular Alcohol Consumption

NCT05125783 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 287

Last updated 2025-02-06

No results posted yet for this study

Summary

Alcohol use is the second leading cause of preventable death after smoking. The Evin law was built in 1991 with the goal of reducing exposure to alcohol marketing among the youngest. But this law is currently extremely weakened, and in a press release of February 26, 2018, the French Society of Alcoology is alarmed by these developments.

Studies on the impact of alcohol marketing focus for the most part on young adolescents and the links between marketing exposure and alcohol initiation. But beyond these links, little work has been done on the impact of alcohol marketing on vulnerable subjects with regular alcohol consumption. Alcohol consumption is one of the very first causes of hospitalization in France. The damage is often limited to the notion of risks of dependence, but it can appear as soon as consumption of 1 standard unit/day and mainly concerns the 45-64 year olds. To investigator knowledge, there are no studies on the impact of alcohol marketing carried out among regular alcohol users with moderate or severe alcohol use disorders.

Conditions

  • Alcohol Abuse

Interventions

OTHER

questionnaire

Completion of the questionnaire by the patient after consultation with the practitioner.

Sponsors & Collaborators

  • Ecole des Hautes Etudes en Santé Publique

    collaborator OTHER

  • University Hospital, Brest

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2023-12-07
Completion
2023-12-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05125783 on ClinicalTrials.gov